Toujeo Max Injection, Solution
Product Images NDC 50090-4177

Product Visual Gallery

This gallery contains 51 technical images submitted to the FDA as part of the official labeling for Toujeo Max (NDC 50090-4177). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904177)

TOUJEO Max 300 Units/mL injection, solution, subcutaneous by A-S Medication Solutions. The label states 300 units per mL with two prefilled pens containing 900 units each. Storage instructions include refrigerating at 36 to 46 degrees Fahrenheit, do not freeze.*

FDA Label Image

Chemical Structure (Toujeo 01)

Chemical structure diagram of insulin glargine shows the peptide chains A and B with amino acid residues labeled, illustrating disulfide bonds connecting cysteine residues for this injectable diabetes medication.*

FDA Label Image

Figure 1 (Toujeo 02)

A line graph depicting glucose infusion rate (GIR) in mg/kg•min over 36 hours following subcutaneous injection. The graph shows GIR values on the vertical axis and time after injection in hours on the horizontal axis, illustrating changes in glucose infusion rate after administration of TOUJEO Max 300 U/mL at a dose of 0.4 units/kg.*

FDA Label Image

Figure (Toujeo 03)

An illustration showing a human figure with highlighted areas labeled upper arms, stomach, and thighs, indicating common sites for subcutaneous injection administration.*

FDA Label Image

Figure (Toujeo 04)

An instructional diagram of the TOUJEO Max insulin glargine 300 U/mL injection pen, showing labeled parts including the pen cap, cartridge holder with rubber seal and insulin scale, plunger, dose window with dose pointer, dose selector, and injection button. The plunger is noted as visible only after several injections.*

FDA Label Image

Figure (Toujeo 05)

TOUJEO Max 300 Units/mL injection pen label showing branding and product information. The label specifies insulin glargine injection, 300 Units per mL, for subcutaneous use to treat diabetes. The label includes dosing indicators and is marked by A-S Medication Solutions.*

FDA Label Image

Figure (Toujeo 06)

Image of a TOUJEO Max insulin glargine injection pen, solution for subcutaneous use. The pen is labeled with lot number 123XY and expiration date 2029-10-31. The label includes a QR code and the pen has a green cap. This product is a 300 U/mL strength by A-S Medication Solutions.*

FDA Label Image

Figure (Toujeo 07)

An instructional diagram showing how to hold the TOUJEO Max insulin glargine injection pen. The left side depicts a hand gripping the cartridge section with visible dosage markings up to 300 units, while the right side shows a hand holding the pen cap, indicated by a blue arrow to slide or remove it.*

FDA Label Image

Figure (Toujeo 08)

The image shows a partial view of a TOUJEO Max injection pen containing insulin glargine 300 U/mL solution for subcutaneous use. The pen has a green color with a light green label area and a white rectangular space for writing or labeling. The label also features some green and blue dot patterns on the right side. The labeler is A-S Medication Solutions.*

FDA Label Image

Figure (Toujeo 09)

Illustration showing a pair of hands peeling off a protective paper covering from a small green injectable vial or pen, indicating preparation for subcutaneous injection.*

FDA Label Image

Figure (Toujeo 10)

An instructional illustration showing hands removing the cap from a small vial or cartridge, likely demonstrating preparation steps for subcutaneous injection administration.*

FDA Label Image

Figure (Toujeo 11)

An instructional diagram showing how to safely remove the needle from a TOUJEO Max insulin glargine injection pen. It depicts two hands twisting the needle cap off in a clockwise direction, and a warning inset highlighting not to pull the needle straight off.*

FDA Label Image

Figure (Toujeo 12)

Illustration showing the preparation and insertion of a pen needle onto an insulin pen device, demonstrating proper handling for subcutaneous injection. The right-hand side depicts a hand placing the pen needle cap onto a surface, while the left-hand side shows the insulin pen with the needle attached, ready for use.*

FDA Label Image

Figure (Toujeo 13)

An instructional illustration showing the preparation of an injection. One hand is holding a syringe with a needle above an open vial or bottle, and the other hand is holding the vial's cap being removed or replaced. The image depicts the steps to prepare the subcutaneous injection of TOUJEO Max insulin glargine solution.*

FDA Label Image

Figure (Toujeo 14)

An instructional diagram showing a hand holding a TOUJEO Max insulin glargine injection pen. The illustration highlights adjusting the dose by turning the dial to select the desired unit amount, with a zoomed-in view of the dose indicator displaying numbers for dose selection.*

FDA Label Image

Figure (Toujeo 15)

An instructional illustration showing a hand holding an insulin pen labeled TOUJEO Max, insulin glargine 300 U/mL. The image focuses on the pen needle priming step, with a close-up inset displaying insulin being expelled from the needle tip as the user presses the dose knob. An upward arrow on the pen indicates the direction to push for priming before injection.*

FDA Label Image

Figure (Toujeo 16)

TOUJEO Max insulin glargine 300 units/mL injection pen for subcutaneous use by A-S Medication Solutions. The pen is shown with a dosage window indicating selected units and a clear label featuring product name and strength.*

FDA Label Image

Figure (Toujeo 17)

Illustration showing a person holding a TOUJEO Max insulin glargine injection pen. The person is using their thumb and forefinger to turn the dose selector dial on the pen, as indicated by a blue arrow, likely to set the dose for subcutaneous injection.*

FDA Label Image

Figure (Toujeo 18)

An illustration depicting the dosage window of an insulin pen. It shows the numbers 28, 29, 30, 31 on a rotating dial, highlighting the mechanism for setting injection units on an insulin pen device.*

FDA Label Image

Figure (Toujeo 19)

An illustration of a dosage selector dial showing adjustable insulin units, highlighting the numbers 28 and 30, representing increments for injection dosing.*

FDA Label Image

Figure (Toujeo 20)

An instructional illustration showing a hand holding a TOUJEO Max injection pen with the needle inserted into the skin for a subcutaneous injection. The syringe is aligned horizontally with an arrow indicating the direction for the injection.*

FDA Label Image

Figure (Toujeo 21)

An instructional illustration showing how to hold and remove the cap from a prefilled pen injector. The diagram highlights proper hand positioning and removal technique in a blue circle, and incorrect thumb placement in a red circle with a cross.*

FDA Label Image

Figure (Toujeo 22)

An instructional illustration showing a hand holding a Toujeo Max insulin glargine injection pen for subcutaneous administration. The image highlights the injection procedure with close-up insets emphasizing the correct dial setting on the pen and holding the pen in place for 5 seconds after injection to ensure proper delivery of the dose.*

FDA Label Image

Figure (Toujeo 23)

An instructional illustration showing hands preparing a TOUJEO Max insulin glargine injection pen. The image depicts one hand holding the pen while the other hand removes the protective cap by pulling it straight off. An arrow indicates the direction to remove the cap, emphasizing preparation steps for subcutaneous injection.*

FDA Label Image

Figure (Toujeo 24)

An instructional illustration showing a hand holding a pre-filled injection device for TOUJEO Max (insulin glargine) 300 U/mL. It depicts twisting the dose dial and pressing the injection button with arrows indicating the direction of twisting and pressing actions for administering the subcutaneous injection.*

FDA Label Image

Figure (Toujeo 25)

An instructional illustration showing two hands removing a foil seal from a bottle while holding a small cap or stopper. The image appears to be part of a preparation or administration guide for an injectable solution.*

FDA Label Image

Figure (Toujeo 26)

An instructional illustration showing hands connecting the cartridge of an injectable drug device to the pen injector. The image depicts the step of inserting the cartridge into the pen with a blue arrow indicating the direction of assembly.*

FDA Label Image

Figure (Toujeo 27)

An instructional anatomical illustration showing preferred injection sites for subcutaneous administration of insulin glargine. Highlighted areas include the upper arms, stomach, and thighs on a front and back human figure outline. The labeled regions indicate common injection locations for the specified medication.*

FDA Label Image

Figure (Toujeo 28)

Illustration of the TOUJEO Max SoloStar insulin glargine injection pen showing labeled parts including the pen cap, cartridge holder, rubber seal, insulin scale, plunger, dose window, insulin name and strength (300 Units/mL), dose selector, dose pointer, and injection button, designed for subcutaneous use.*

FDA Label Image

Figure (Toujeo 29)

TOUJEO Max 300 U/mL injection, solution label visible on an insulin delivery pen. The label shows the proprietary name TOUJEO Max, the generic name insulin glargine injection, solution for subcutaneous use, and dosing units 300 Units/mL. The pen is marked for single patient use and includes a dosage adjustment sliding scale indicator showing adjustments by 2 units. The labeler is A-S Medication Solutions.*

FDA Label Image

Figure (Toujeo 30)

The image shows a TOUJEO Max insulin glargine injection pen, solution for subcutaneous use. It is a 300 U/mL dosage form, labeled by A-S Medication Solutions. The pen has a green patterned section near the top and a white cap with a green tip on the end. Lot number 123XY and expiration date 2029-10-31 are printed on the label.*

FDA Label Image

Figure (Toujeo 31)

An instructional illustration showing hands assembling an insulin pen device. The left hand holds a cartridge labeled with 300 U/mL, while the right hand pulls the pen cap off, indicated by a blue arrow pointing right. This image demonstrates preparing the injection pen for use.*

FDA Label Image

Figure (Toujeo 32)

Illustration showing a close-up section of the TOUJEO Max insulin glargine injection pen featuring the dose display window area, with part of the label indicating the concentration of 300 Units/mL visible on the right side of the pen barrel.*

FDA Label Image

Figure (Toujeo 33)

An instructional illustration showing hands holding a pen-type injector device being cleaned with a cloth or wipe. One hand holds the pen, while the other hand uses the cloth to wipe the metal connection end of the device.*

FDA Label Image

Figure (Toujeo 34)

An instructional illustration showing two hands holding an insulin vial and a syringe. The image depicts the process of withdrawing insulin glargine solution for subcutaneous injection, relevant to TOUJEO Max 300 U/mL.*

FDA Label Image

Figure (Toujeo 35)

An instructional illustration showing a person preparing to remove the protective cap from a TOUJEO Max (insulin glargine) 300 U/mL injection pen. The image includes a close-up inset with a red arrow indicating the correct method to pull off the cap, emphasizing proper handling before subcutaneous injection.*

FDA Label Image

Figure (Toujeo 36)

An instructional illustration showing a hand holding a TOUJEO Max 300 U/mL insulin glargine pen while preparing a dose, with the pen needle tip contacting a vial cap on a flat surface. The image is intended to demonstrate the process of injection preparation for the subcutaneous insulin injection solution.*

FDA Label Image

Figure (Toujeo 37)

An instructional illustration showing the removal of a protective cap from the top of a container, with a hand holding the cap and an injection device positioned nearby with an arrow indicating the cap removal step.*

FDA Label Image

Figure (Toujeo 38)

An instructional illustration showing a hand adjusting the dose selector on a Toujeo Max SoloStar insulin glargine injection pen. A close-up inset highlights the dose window indicating '4 units selected' for subcutaneous injection.*

FDA Label Image

Figure (Toujeo 39)

Illustration showing a person holding an insulin pen injection device with an emphasis on priming the needle. The inset zooms in on the needle tip, depicting insulin being expelled as a spray, indicating the device is ready for subcutaneous use.*

FDA Label Image

Figure (Toujeo 40)

TOUJEO Max 300 Units/mL insulin glargine injection pen by A-S Medication Solutions. This subcutaneous injection device is labeled for single patient use only. The pen has a dose window with numbered increments and an adjustment range of 2 units. The NDC is 50090-4177.*

FDA Label Image

Figure (Toujeo 41)

An instructional illustration showing a person holding a TOUJEO Max SoloStar injection pen (insulin glargine 300 U/mL). The image demonstrates the step of adjusting the dose by turning the dose knob, indicated by a blue arrow, as part of preparing the pen for subcutaneous injection.*

FDA Label Image

Figure (Toujeo 42)

An illustration showing a close-up view of an insulin pen dose dial window, displaying numbers 56, 60, and 64, indicating dose measurement increments.*

FDA Label Image

Figure (Toujeo 43)

An illustration showing a close-up of a dose selector window on an insulin pen, with the dial set between 56 and 60 units.*

FDA Label Image

Figure (Toujeo 44)

An instructional illustration showing a hand holding a TOUJEO Max insulin glargine 300 U/mL injection pen. The illustration depicts the user pressing the dose knob with the thumb, as indicated by a blue arrow pointing left, likely demonstrating dose delivery technique.*

FDA Label Image

Figure (Toujeo 45)

An instructional illustration showing how to correctly adjust the dose dial on a TOUJEO Max insulin glargine 300 U/mL injection pen. The image indicates proper thumb placement for turning the dial to align a dose indicator with a mark, and highlights incorrect thumb positioning with a red circle and slash mark.*

FDA Label Image

Figure (Toujeo 46)

Instructional illustration showing a hand holding a TOUJEO Max insulin glargine injection pen for subcutaneous use. The image highlights pressing the dose button and waiting for 5 seconds, indicating proper injection technique timing.*

FDA Label Image

Figure (Toujeo 47)

An instructional diagram showing a hand holding a prefilled insulin glargine injection pen labeled TOUJEO Max 300 U/mL, demonstrating the removal of the needle cap by pulling it straight off. The dose window on the pen shows a scale from 100 to 900 units.*

FDA Label Image

Figure (Toujeo 48)

An instructional illustration showing hands holding a TOUJEO Max insulin glargine injection pen. The image depicts lifting or rotating the release button and pressing the injection button, indicated by blue arrows, demonstrating the injection process for the subcutaneous delivery of the 300 U/mL insulin solution.*

FDA Label Image

Figure (Toujeo 49)

An instructional illustration showing hands removing a cap from a vial, demonstrating how to open or prepare the medication container for use.*

FDA Label Image

Figure (Toujeo 50)

An instructional diagram showing hands holding an insulin glargine prefilled pen labeled TOUJEO Max 300 U/mL. The illustration demonstrates removing the pen cap by pulling it away from the pen body, indicated by a blue arrow pointing left.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.